Legend Biotech’s Carvykti, a cell therapy for relapsed or lenalidomide-refractory multiple myeloma, demonstrated significant improvement in overall survival compared to standard therapies in a three-year follow-up study. The data presented at the International Myeloma Society Annual Meeting suggests that Carvykti could become a leading treatment option for patients after their first relapse.